INIS
breasts
100%
cancer
100%
patients
91%
receptors
79%
hormones
65%
therapy
49%
humans
46%
growth factors
46%
netherlands
45%
metastases
40%
risks
13%
populations
12%
kinases
12%
implementation
11%
chemotherapy
10%
diseases
10%
hazards
10%
hospitals
6%
weight
5%
Keyphrases
Advanced Breast Cancer
67%
Netherlands
47%
Hormone Receptor-positive
46%
Cancer Registry
34%
Human Epidermal Growth Factor Receptor 2 (HER2)
34%
Overall Survival
31%
Metastatic Breast Cancer
28%
Cyclin-dependent Kinase 4 (CDK4)
24%
HER2+
22%
Time Trends
22%
Human Epidermal Growth Factor Receptor 2-negative
22%
Progression-free Survival
21%
Hormone Receptor
19%
Patient Survival
15%
Confidence Interval
14%
Line of Therapy
14%
Pertuzumab
14%
Systemic Therapy
14%
Treatment Choice
13%
Chemotherapy
13%
Cyclin-dependent Kinase 4/6 Inhibitors
12%
HER2-positive
12%
HER2 Metastatic Breast Cancer
12%
Dutch
12%
Trastuzumab
11%
Body Mass Index
11%
Prognostic Impact
11%
Population-based Retrospective Cohort Study
11%
Real-world Treatment Patterns
11%
High Risk
11%
Medicine and Dentistry
Breast Cancer
52%
Hormone Receptor
44%
Metastatic Breast Cancer
33%
Epidermal Growth Factor Receptor 2
25%
Gamma Urogastrone
25%
Cancer Registry
23%
Overall Survival
22%
Chemotherapy
13%
CDK4/6 Inhibitor
12%
Patient Characteristics
11%
Cyclin-Dependent Kinase 4
11%
Observational Study
11%
Retrospective Cohort Study
11%
Progression Free Survival
11%
Cyclin-Dependent Kinase
11%
Biopsy Technique
9%
Systemic Therapy
9%
Hormone Therapy
7%
Cancer Diagnosis
6%
Targeted Therapy
6%
Pertuzumab
5%